Activated CAFs can trigger melanoma progression and resistance to BRAF/MEK inhibitors via the release of soluble molecules including neuregulin 1 and hepatocyte growth factor (HGF) [73,74] as well as fibronectin [75,76]. The gene discussed is BRAF; the disease is melanoma.